Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for PH-HFpEF
NCT03629340Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Feb 2019
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liquid metformin (Aspargo Labs) in pulmonary hypertension (PH) and heart failure (HF) (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Mean Pulmonary Arterial Pressure at 12 weeks. Started Feb 2019; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
pulmonary hypertension (PH)heart failure (HF)
Beyond the preview
Go deeper on NCT03629340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03629340.